Curis, Inc.
Candidate for basal cell carcinoma under co-development by Genentech, partner
Published in Drug Law Weekly, May 3rd, 2005
Curis, Inc., (CRIS), a therapeutic drug-development company, announced that Genentech, Inc., (DNA) has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate human clinical investigation of a drug candidate for the topical treatment of basal cell carcinoma, the most common form of all human cancers with approximately 800,000-1,000,000 new cases reported every year in the U.S.
This drug candidate, an antagonist of the Hedgehog signaling pathway, was discovered by Curis and is being co-developed through a collaboration between Genentech and Curis.
Daniel Passeri, president and CEO of Curis, said, "The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2005-05-03)
More Articles from Drug Law Weekly
- ARC Pharmaceuticals, Inc.
Pharmaceutical firm granted U.S. patent related to surgical adhesion therapy - Ark Therapeutics Group plc
License granted to Boehringer Ingelheim for access to technology - Biophan Technologies, Inc.
Biomedical device firm expands intellectual property portfolio - Dalton Pharma Services
Dalton Chemical Laboratories, Inc. announces name change - Healthcare Group Purchasing Industry Initiative
Healthcare group purchasing organizations promote business practices - Hollis-Eden Pharmaceuticals, Inc.
Phase I clinical study on NEUMUNE begins - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
